tbuckley/cabot-search huggingface dataset:
Pain sensitivity and aromatase inhibitor (AI)-associated arthralgias (AIAA).
Authors: Norah Lynn Henry, Steven Harte, Anna S.C. Conlon, Kent A. Griffith, Gabriela Ramirez, Jill Hayden, Jeffrey B. Smerage, Anne F. Schott, Daniel F. Hayes, David A. Williams, Daniel A Clauw
Journal: Journal of Clinical Oncology (2013)

9615 Background: AIAA affect up to half of AI-treated women with early stage breast cancer, and can lead to treatment discontinuation in 20-30%. The etiology is thought to be related to estrogen deprivation although the mechanism is unknown. In premenopausal women, lower estrogen levels have been associated with increased pain. Impaired descending pain inhibitory pathways, which may be a risk factor for developing chronic pain, have also been associated with lower estrogen levels. We prospectively tested whether AI-induced estrogen deprivation alters pain sensitivity, thereby increasing the risk of developing AIAA. Methods: Fifty postmenopausal women with early stage breast cancer initiating AI therapy were enrolled to the study. Subjects underwent experimental pressure pain testing and conditioned pain modulation (CPM) assessment and completed symptom questionnaires prior to AI initiation and after 3 months. Positive CPM values (&gt;0) signify impaired descending pain inhibition. Serum estradiol concentrations were determined using an ultrasensitive assay. T-tests, Fisher’s exact test, and linear regression models were used to assess associations among baseline (BL) experimental pain measures, patient-reported pain, and clinical factors. P values &lt;0.05 were considered statistically significant. Results: All subjects had decreased serum estradiol concentrations with AI therapy. No statistically significant change in pressure pain threshold or CPM with AI therapy was detected. In addition, no association between change in patient-reported pain with AI therapy and change in pain threshold or CPM was identified. Patients demonstrated impaired CPM at baseline (mean 8.0, SD 14.9), and this impairment was greater in patients previously treated with chemotherapy 14.4 vs 2.0, p=0.006), with non-significant trends towards this being more pronounced in those with more severe pain. Conclusions: AI therapy did not impact pressure pain threshold or CPM, suggesting that AIAA is not likely due to pain amplification from estrogen depletion. Studies examining chemotherapy-induced changes in pain processing are needed to better understand how these alterations might contribute to the pain that these patients often develop.
TLR7/8 Differentially Regulates Fcγ Receptor Expression and Function.
Authors: Jonathan P Butchar, Payal Mehta, Steven E Justiniano, Kristan D Guenterberg, Thirumala-Devi Kanneganti, Amal Amer, Natarajan Muthusamy, David Jarjoura, Clay B Marsh, William E Carson, John C Byrd, Susheela Tridandapani
Journal: Blood (2009)
Physiology and Pathophysiology of the Intrarenal Renin-Angiotensin System: An Update
Authors: Tianxin Yang, Chuanming Xu
Journal: Journal of the American Society of Nephrology (2017)

The renin-angiotensin system (RAS) has a pivotal role in the maintenance of extracellular volume homeostasis and blood pressure through complex mechanisms. Apart from the well known systemic RAS, occurrence of a local RAS has been documented in multiple tissues, including the kidney. A large body of recent evidence from pharmacologic and genetic studies, particularly those using various transgenic approaches to manipulate intrarenal levels of RAS components, has established the important role of intrarenal RAS in hypertension. Recent studies have also begun to unravel the molecular mechanisms that govern intrarenal RAS activity. This local system is under the control of complex regulatory networks consisting of positive regulators of (pro)renin receptor, Wnt/ β -catenin signaling, and PGE 2 /PGE 2 receptor EP 4 subtype, and negative regulators of Klotho, vitamin D receptor, and liver X receptors. This review highlights recent advances in defining the regulation and function of intrarenal RAS as a unique entity separate from systemic angiotensin II generation.
Outcomes Associated With Early Preventive Dental Care Among Medicaid-Enrolled Children in Alabama
Authors: Justin Blackburn, Michael A. Morrisey, Bisakha Sen
Journal: JAMA Pediatrics (2017)

There is a recommendation for children to have a dental home by 6 months of age, but there is limited evidence supporting the effectiveness of early preventive dental care or whether primary care providers (PCPs) can deliver it.
In vitro mineralisation of grafted ePTFE membranes carrying carboxylate groups
Authors: Norsyahidah Mohd Hidzir, David J.T. Hill, Darren Martin, Lisbeth Grøndahl
Journal: Bioactive Materials (2017)

In vitro mineralisation in simulated body fluid (SBF) of synthetic polymers continues to be an important area of research as the outcomes cannot be predicted. This study evaluates a series of ePTFE membranes grafted with carboxylate-containing copolymers, specifically using acrylic acid and itaconic acid for grafting. The samples differ with regards to graft density, carboxylate density and polymer topology. The type and amount of mineral produced in 1.5 × SBF was dependent on the sample characteristics as evident from XPS, SEM/EDX, and FTIR spectroscopy. It was found that the graft density affects the mineral phases that form and that low graft density appear to cause co-precipitation of calcium carbonate and calcium phosphate. Linear and branched graft copolymer topology led to hydroxyapatite mineralisation whereas crosslinked graft copolymers resulted in formation of a mixture of calcium-phosphate phases. This study demonstrates that in vitro mineralisation outcomes for carboxylate-containing graft copolymers are complex. The findings of this study have implications for the design of bioactive coatings and are important for understanding the bone-biomaterial interface.
Assessing the Appropriateness of Carotid Revascularization
Authors: Ravinder Kang, Jesse A. Columbo, Philip P. Goodney
Journal: JAMA Surgery (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Association of Oncogenic Mutations in Patients With Advanced Cutaneous Squamous Cell Carcinomas Treated With Cetuximab
Authors: Alexandra Picard, Florence Pedeutour, Frédéric Peyrade, Laurence Saudes, Valérie Duranton-Tanneur, Emmanuel Chamorey, Nathalie Cardot-Leccia, Anne Sudaka, Marc Ettaiche, Maxime Benchetrit, Gilles Poissonnet, Nicolas Weinbreck, Bérengère Dadone, Jean-Philippe Lacour, Thierry Passeron, Henri Montaudié
Journal: JAMA Dermatology (2017)

<h3>Importance</h3> Cetuximab was recently proposed for advanced cutaneous squamous cell carcinomas (cSCC); however, its efficacy is inconsistent and identification of predictive biomarkers for response is necessary. <h3>Objective</h3> To search for somatic mutations of the<i>HRAS, KRAS, NRAS, BRAF</i>, and<i>EGFR</i>genes in patients with advanced cSCC treated with cetuximab; and to investigate the efficacy and tolerance of cetuximab according to these mutations. <h3>Design, Setting, and Participants</h3> A multicentric and retrospective study of 31 patients (22 men, 9 women) with histologically confirmed advanced cSCC carried out in 1 department of dermatology and 2 departments of medical oncology in France between January 2008 and December 2014. The median age of participants was 86 years (range, 48-96 years). <h3>Interventions</h3> Mutational status was determined by pyrosequencing method, allelic discrimination, or Sanger sequencing. Patients were treated by single-agent cetuximab. <h3>Main Outcomes and Measures</h3> The primary end point was the incidence of somatic mutations of the<i>RAS, BRAF</i>, and<i>EGFR</i>genes and association of cetuximab efficacy with these mutations was investigated by using Fisher test. Secondary end points were the disease control rate (DCR) at week 6, the progression free-survival (PFS), overall survival (OS), and safety profile of cetuximab. <h3>Results</h3> Thirty-one samples of cSCC from 31 patients were analyzed. Only 2<i>RAS</i>mutated samples (6.5%) were identified. The first harbored a<i>NRAS</i>point mutation (c.35G&gt;A) in codon 12, resulting in a p.G12D substitution. The second sample presented a<i>HRAS</i>point mutation (c.38G&gt;T) in codon 13, resulting in a p.G13V substitution. No mutation of<i>KR</i>AS,<i>BRAF</i>, and<i>EGFR</i>genes at the investigated loci was found. Two patients with<i>NRAS</i>and<i>HRAS</i>mutations showed a partial and complete response to cetuximab, respectively. The mean duration of follow-up was 19 months. At week 6, the disease control rate was 67.8%. The median OS was 13 months and the median PFS was 9 months. All patients could continue cetuximab treatment without dose reduction. <h3>Conclusions and Relevance</h3> Even in elderly patients with advanced cSCC, cetuximab was efficacious and well-tolerated. This suggests that cetuximab is certainly warranted in the treatment of advanced cSCC. However, it is also important to identify tumor specific mutations that may determine response to treatment and prognosis for the disease. We have identified here that the incidence of<i>RAS</i>,<i>BRAF</i>, and<i>EGFR</i>mutations is low in cSCC.
Results of the Randomized I-BFM-SG Trial „Acute Lymphoblastic Leukemia Intercontinental-BFM 2002“ in 5060 Children Diagnosed in 15 Countries on 3 Continents
Authors: Jan Stary, Martin Zimmermann, Myriam Campbell, Luis Castillo, Eduardo Dibar, Svetlana Donska, Alejandro Gonzalez, Shai Izraeli, Dragana Janic, Janez Jazbec, Josip Konja, Emilia Kaiserova, Jerzy Kowalczyk, Gabor Kovacs, Chi-Kong Li, Edina Magyarosy, Alexander Popa, Batia Stark, Yahia Jabali, Jan Trka, Ondrej Hrusak, Iveta Janotova, Hansjörg Riehm, Giuseppe Masera, Martin Schrappe
Journal: Blood (2011)
Erratum: A genome-wide association study of cleft lip with and without cleft palate identifies risk variants near MAFB and ABCA4
Authors: Terri H Beaty, Jeffrey C Murray, Mary L Marazita, Ronald G Munger, Ingo Ruczinski Jacqueline B Hetmanski, Kung Yee Liang, Tao Wu, Tanda Murray, M Daniele Fallin, Richard A Redett, Gerald Raymond, Holger Schwender, Shin C Jin, Margaret E Cooper, Martine Dunnwald, Maria A Mansilla, Elizabeth Leslie, Stephen Bullard, Andrew C Lidral, Lina M Moreno, Renato Menezes, Alexandre R Vieira, Aline Petrin, Allen J Wilcox, Rolv T Lie, Ethylin W Jabs, Yah Huei Wu-Chou, Philip K Chen, Hong Wang, Xiaoqian Ye, Shangzhi Huang, Vincent Yeow, Samuel S Chong, Sun Ha Jee, Bing Shi, Kaare Christensen, Mads Melbye, Kimberly F Doheny, Elizabeth W Pugh, Hua Ling, Eduardo E Castilla, Andrew E Czeizel, Lian Ma, L Leigh Field, Lawrence Brody, Faith Pangilinan, James L Mills, Anne M Molloy, Peadar N Kirke, James M Scott, Mauricio Arcos-Burgos, Alan F Scott
Journal: Nature Genetics (2010)
Prognostic Role of Glutathione S-Transferase (GST) Polymorphisms in Acute Myeloid Leukemia.
Authors: Maria Teresa Voso, Stefan Hohaus, Francesco Guidi, Emiliano Fabiani, Francesco D’Alo’, Silia Groener, Daniela Spaeth, Konstanze Dohner, Giuseppe Leone, Hartmut Dohner, Richard F. Schlenk
Journal: Blood (2007)
Abstract P2-12-03: Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life
Authors: PS Giron, CA Haddad, SL Rizzi, TL Pinheiro, RP Luz, AP Nazário, G Facina
Journal: Cancer Research (2017)

Abstract Objective: To investigate the benefits of acupuncture in relation to the shoulder muscle strength and quality of life in women undergoing surgical treatment for breast cancer. Methods: Women with breast cancer, aged 18 years or more, with pain level ≥ 3 in the Visual Analog Scale in shoulder girdle or upper limb three months after surgery, were included in this prospective study. The patients were randomly divided into two groups and received weekly treatment for 10 sessions. Kinesiotherapy group (G1): treated with pre-defined standard kinesiotherapy, lasting 30 minutes. Group Acupuncture + Kinesiotherapy (G2): treated with the same Kinesiotherapy group protocol followed by another 30 minutes of acupuncture using pre-defined points. Acupuncture points used were as follows: CV 3, SP 9, ST 36, KD 7, LV 3, GB 21, LI 15, SJ 14, LU 5, LI 4, ST 38 and BL 60. Patients were evaluated at baseline, after five weeks and at the end of 10 weeks. Parameters studied were: clinical profile and socio-demographic data, muscle strength and quality of life. Results: 48 patients completed treatment, 24 in each group. Regarding shoulder muscle strength, all movements showed improvement and there was no statistical difference between groups. However, when analyzing intragroup changes, improvement of flexion and internal rotation were observed in G1 and increase of all movements were found in G2. Concerning EORTC, there was statistically significant difference between groups of pain symptom in the 5th session, with better score in patients of G2 in relation to G1. About EORTC intragroups results, G1 showed improvement in physical function, pain and insomnia; and G2 in performance roles, fatigue and pain. Conclusion: According to this prospective study, kinesiotherapy and acupuncture had a positive effect on the shoulder muscle strength and quality of life of patients. Keywords: 1. Breast cancer. 2. Rehabilitation. 3. Acupuncture. 4. Muscle Strength. 5. Quality of life. Citation Format: Giron PS, Haddad CA, Rizzi SL, Pinheiro TL, Luz RP, Nazário AP, Facina G. Prospective study of acupuncture in the rehabilitation of women undergoing surgical treatment of breast cancer in relation to the strength and quality of life [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr P2-12-03.
Tetraspanin 6: a pivotal protein of the multiple vesicular body determining exosome release and lysosomal degradation of amyloid precursor protein fragments
Authors: Francesc X. Guix, Ragna Sannerud, Fedor Berditchevski, Amaia M. Arranz, Katrien Horré, An Snellinx, Amantha Thathiah, Takaomi Saido, Takashi Saito, Sundaresan Rajesh, Michael Overduin, Samir Kumar-Singh, Enrico Radaelli, Nikky Corthout, Julien Colombelli, Sébastien Tosi, Sebastian Munck, Isabel H. Salas, Wim Annaert, Bart De Strooper
Journal: Molecular Neurodegeneration (2017)

The mechanisms behind Aβ-peptide accumulation in non-familial Alzheimer's disease (AD) remain elusive. Proteins of the tetraspanin family modulate Aβ production by interacting to γ-secretase. We searched for tetraspanins with altered expression in AD brains. The function of the selected tetraspanin was studied in vitro and the physiological relevance of our findings was confirmed in vivo. Tetraspanin-6 (TSPAN6) is increased in AD brains and overexpression in cells exerts paradoxical effects on Amyloid Precursor Protein (APP) metabolism, increasing APP-C-terminal fragments (APP-CTF) and Aβ levels at the same time. TSPAN6 affects autophagosome-lysosomal fusion slowing down the degradation of APP-CTF. TSPAN6 recruits also the cytosolic, exosome-forming adaptor syntenin which increases secretion of exosomes that contain APP-CTF. TSPAN6 is a key player in the bifurcation between lysosomal-dependent degradation and exosome mediated secretion of APP-CTF. This corroborates the central role of the autophagosomal/lysosomal pathway in APP metabolism and shows that TSPAN6 is a crucial player in APP-CTF turnover.
Battle of the Bulge: Aortic Aneurysm Management From Early Modernity to the Present
Authors: Justin Barr
Journal: Annals of Internal Medicine (2017)

For centuries, physicians have recognized aortic aneurysms as an acute threat to life. Therapeutic approaches to the disease began in the 18th century when leading physicians, such as René Laennec and Antonio Valsalva, applied research on circulation and blood coagulation to devise whole-body fasting and bleeding regimens to prevent rupture. After John Hunter's success in ligating arteries to treat peripheral aneurysms, surgeons attempted analogous operations on the aorta, but even the renowned Sir Astley Cooper and William Halsted met with disastrous results. Other clinicians tried various methods of creating intraluminal clots, including the application of such new technologies as electricity and plastic. Vessel repair techniques, pioneered by Alexis Carrel and others in the 20th century, eventually provided a reliably effective treatment. In the past few decades, minimally invasive methods that approach aneurysms endovascularly through small groin incisions have been adopted. A successful 2005 congressional campaign to fund screening for aortic aneurysms brought the disease to national attention and symbolizes current confidence in curing it. Drawing on various published and unpublished sources, this paper elucidates the development of specific treatments for aortic aneurysms over time and more broadly addresses how medicine and surgery apply the knowledge and technology available in particular eras to treat a specific, identifiable, and lethal disease. Examining the evolution of these therapeutic efforts unveils broader trends in the history of medicine. This allows aortic aneurysms to serve as a case study for exploring shifting philosophies in medical history.
A population-based study of the effect of FDG PET/CT in the management of liver-limited colorectal adenocarcinoma (CRC) metastases.
Authors: Maria Yi Ho, Tarnjit Parhar, Don Wilson, Winson Y. Cheung, Howard John Lim
Journal: Journal of Clinical Oncology (2012)

3610 Background: PET/CT scans are publically funded in British Columbia for staging in liver limited metastatic CRC. However, past studies have been equivocal about the utility of PET/CT as some report as high as a 20-30% change in management while others report &lt;10% change in management. Our primary objective was to assess the effect of the addition of PET/CT to CT scanning for the management of liver limited colorectal cancer. Methods: Patients who underwent PET/CT scan for de novo liver limited metastatic disease from 2005-2011 in the province of British Columbia were identified using the PET/CT database. Patients recently completed or currently on chemotherapy were excluded. We determined the concordance rates between CT and PET/CT scans with respect to the extra-hepatic disease, the number of lesions in the liver and the location of liver lesions. Results: 349 patients were identified. The most common indications for PET/CT scans after an initial CT scan were: detection of extrahepatic disease (77%), confirmation of the malignant nature of the liver lesions (8%) and the extent of extrahepatic disease (15%). PET/CT and CT were discordant in 39% of cases for the extent of metastatic disease. PET/CT revealed extrahepatic disease in 27% of the cases for which CT only detected liver limited disease. In contrast, 13% of patients were downstaged when CT liver lesions were demonstrated not to be FDG avid. Concordance of PET/CT and CT scans on the number and location of liver lesions was 52% and 85%, respectively. PET/CT revealed additional number of liver lesions and multilobar disease in 26% and 12% of cases, respectively. Furthermore, the median time between PET/CT and CT were 64.3 days and 64.1 days for concordant and discordant cases (p=0.88). Conclusions: PET/CT scans provided additional information compared to CT scans which could have implications for surgical management. Our study supports the utility and public funding of PET/CT in addition to CT in patients with potentially surgically curable metastatic CRC involving the liver.
Contents, Vol. 4, 1956
Authors: R. Le Coultre, Paul J. Reiter, Heinrich Huebschmann, Ernst Schneider, H.-J. Schumann, F. Pollak, Ferruccio Antonelli, Alice Friedman, Henri Foissin, L. Navratil, E. Kriehüber, R. Wenger
Journal: Psychotherapy and Psychosomatics (1956)
Haploidentical stem cell transplantation and subsequent immunotherapy with antiGD2 antibody for patients with relapsed metastatic neuroblastoma.
Authors: Peter Lang, Toni Illhardt, Martin Ebinger, Patrick Schlegel, Heiko-Manuel Teltschik, Tobias Feuchtinger, Carl Philipp Schwarze, Ruth L Ladenstein, Holger N. Lode, Hans Loibner, Wolfgang Schwinger, Christian Urban, Rupert Handgretinger
Journal: Journal of Clinical Oncology (2015)

10056 Background: Pediatric patients with relapsed metastatic neuroblastomas have a poor prognosis and additional therapeutic strategies are needed. We present results of a phase I/II-trial with subsequent immunotherapy with an anti-GD2mAb (CH14.18/CHO) after HLA mismatched, haploidentical stem cell transplantation (SCT). Methods: T- and B-cell depleted stem cells from parental donors were used in combination with Melphalan140mg/m², Thiotepa10mg/kg, Fludarabin160mg/m² and ATG-F. Infusions with CH14.18/CHOmAb were started on day 60-180 posttransplant: 6 cycles with 20mg/m²/day x 5 days; in cycles 4-6, 1x106 U/m² Interleukin 2 (IL2) was given additionally. The disease status was evaluated with whole body MRI, MIBG scan and bone marrow aspirates. Results: 34 patients with 1st or 2nd metastatic relapse were enrolled. During antibody infusions, endogenous secretion of IL2 was increased (928U/ml prior vs. 1690U/ml post, p < 0.001), which resulted in significantly increased numbers of activated CD69+ Natural Killer (NK) cells (3 vs. 13% p < 0.01). In 5/7 investigated patients, effective ADCC and complement mediated (CDC) anti-tumor effects against neuroblastoma cells were detectable in vitro (85% specific lysis, E:T-ratio = 20:1, BATDA-release). 14/34 patients did not reach the end of the protocol (due to side effects, n = 2; TRM, n = 1; progression or relapse, n = 11). 8/34 patients could maintain a CR, 9/34 patients improved their partial remission and achieved CR, 3/34 patients had stable disease. Thus, success of treatment defined as stable disease or improvement was shown in 59%. Progression free survival at 2 and 3 years was 55% and 38% (median follow up: 550 days). Frequent side effects were pain, fever and CRP elevation; rare side effects comprised SIRS/capillary leak syndrome, seizures, and accommodation disturbances. Only 1 patient developed transient acute GvHD grade II. Conclusions: CH14.18/CHO infusions after haploidentical stem cell transplantation appear to be feasible without increased risk of inducing GvHD. Results of our study also suggest an anti tumor effect of the new, donor-derived immune system in vitro and in vivo. Clinical trial information: NCT02258815.